

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of

Peart, et al.

Serial No.: Unassigned

Group Art Unit: Unassigned

Filed: Concurrently

Examiner: Unassigned

For: DELTA9 TETRAHYDROCANNABINOL (DELTA9 THC) SOLUTION
METERED DOSE INHALERS AND METHODS OF USE

Commissioner of Patents and Trademarks
Alexandria, Virginia 22313

INFORMATION DISCLOSURE STATEMENT


Sir:

Under the provisions of 37 C.F.R. §1.97 through §1.99 and pursuant to applicant's duty of disclosure under 37 C.F.R. §1.56, applicant respectfully brings the following documents, listed on the attached form PTO-1449's, to the attention of the Examiner in charge of the above-identified application. Copies of the listed documents can be found in the parent case (Issued Patent 6,509,005 Issued on January 21, 2003 and in a Continuation in part application US Serial Number 09/944,221.)

This citation does not constitute an admission that the references are relevant or material to the claims. They are only cited as constituting related art of which the applicant is aware.

It is respectfully requested that the documents be considered by the Examiner and formally made of record in this application.

Respectfully submitted,



Ruth Tyler-Cross

Registration No.: 45,922

703-787-9400

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

ATTY DOCKET NO.
02940086A

SERIAL NO.
09/944221

APPLICANT(S)
J. Peart et al.

FILING DATE
9-4-01

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Bliss, C.I. (1967). Statistics in Biology; New York; McGraw-Hill; pp 439
		Dalby, R.N., et al.; Medical Devices for the Delivery of Therapeutic Aerosols to the Lungs; Inhalation Aerosols: Physical and Biological Basis for Therapy; Lung Biology in Health and disease, Vol. 94, pp. 441-451.
		Gill, E.W., et al.; Blood and Brain Levels of Delta1-tetrahydrocannabinol in mice -- The effect of 7-hydroxy-delta1-tetrahydrocannabinol; Biochemical Pharmacology, Vol. 23, pp 1140-1143, 1974.
		Joy, J.E., et al.; Marijuana and Medicine: Assessing the Science Base; Washington DC: National Academy Press; pp. 1-81.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OF

-FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 98-70	SERIAL NO. 09/944221
APPLICANT: Joanne Peart et al.		
FILING DATE: 9-4-01		GROUP:

REFERENCE DESIGNATION U.S. PATENT DOCUMENTS

EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPRO.)

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

		Workshop on the medical utility of marijuana. National Institutes of Health. August 1997.
		Olsen, J.L., Lodge, J.W., Shapiro, B.J. and Tashkin, D.P. (1976). An inhalation aerosol of Δ^9 -tetrahydrocannabinol. <i>Journal of Pharmacy and Pharmacology</i> , 28:86.
		Thornton, Jacquil, (13 June 1999). Cannabis inhalers in first legal health test. <i>Electronic Telegraph, UK News Summary</i> , www.telegraph.co.uk , Issue 1479.
		Tashkin, D.P., Reiss, S., Shapiro, B.J., Calvarese, B., Olsen, J.L. and Lodge, J.W. (1977). Bronchial effects of aerosolized Δ^9 -tetrahydrocannabinol in healthy and asthmatic subjects. <i>American Review of Respiratory Disease</i> , 115:57-65.
		Williams, S.J., Hartley, J.P.R., Graham, J.D.P. (1976). Bronchodilator effect of Δ^1 -tetrahydrocannabinol administered by aerosol to asthmatic patients. <i>Thorax</i> , 31:720-723.

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

-FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANTS INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 98-70	SERIAL NO. 09/944 221
	APPLICANT: J. Pearl, et al.	
	FILING DATE: 9-4-01	GROUP:

REFERENCE DESIGNATION U.S. PATENT DOCUMENTS

EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPRO.)

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

		Long-Term Efficacy and Safety of Dronabinol for Acquired Immunodeficiency Syndrome-Associated Anorexia, Journal of Pain and Symptom Management; Vol. 14 No. 1 July 1997 pgs 7-14
		Dronabinol as a Treatment for Anorexia Associated with Weight Loss in Patients with AIDS; Journal of Pain and Symptom Management; Vol. 10 No. 2; February 1995; pgs 89-97
		Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy; Investigational New Drugs 6:243-246; (1988); Mary McCabe, Frederick P. Smith, John S. Macdonald, Paul V. Woolley, Deborah Goldberg, and Philip S. Schien; Divisional of Medical Oncology, Vincent T. Lombardi Cancer Research Center, Dept. of Medicine. Georgetown University
		Tetrahydrocannabinol for Refractory Vomiting Induced by Cancer Chemotherapy; JAMA March 28, 1980-Vol 243, No. 12
		ANTIEMETICS-SALLAN, ET AL. The New England Journal of Medicine; Jan. 17, 1980; Vol 302 No. 3; pgs 135-138
		Delta-9-Tetrahydrocannabinol as an Antiemetic for Patients receiving Cancer Chemotherapy; December 1979; Annals of Internal Medicine; Vol 91 No. 6; pgs. 825-830
		Delta-9-Tetrahydrocannabinol as an Antiemetic in Cancer Patients Receiving High-Dose Methotrexate; December 1979; Annals of Internal Medicine; Vol. 91 No. 6; pgs. 820-824
		Analgesic effect of Delta-9-tetrahydrocannabinol; Dept. of Psychiatry and Internal Medicine, University of Iowa College; Feb-March 1975; pgs. 139-143
		Analgesic Properties of delta-9-tetrahydrocannabinol and codeine; Depart., of Psychiatry and Medicine, University of Iowa; published March 29, 1975; pgs 84-89
		The effect of orally and rectally administered 9-tetrahydrocannabinol on spasticity: A pilot study with 2 patients; Institute of Pharmacy, University of Bern; International Journal of Clinical Pharmacology and Therapeutics, Vol 34 No. 10-1996 (446-452)
		Delta-9-THC in the Treatment of Spasticity Associated with Multiple Sclerosis; Dept. of Psychiatry at U.C.L.A; 1988 Hawthorne Press; pgs. 39-50.
		Tetrahydrocannabinol for Tremor in Multiple Sclerosis; David Clifford, MD; Division of Clinical Neuropharmacology and Dept. of Neurology and Neurological Surgery Washington School of Medicine, Published December 12, 1982; Annals of Neurology Vol 13 No. 6 June 1983; pgs 669-671
		Treatment of Human Spasticity with 9-Tetrahydrocannabinol; J. Clin Pharmacol. 1981;21:413S-416S
		Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial; Eur Arch Psychiatry Clin Neurosci 1990;240(1):1-4
		Effect of Marijuana on Intraocular and Blood Pressure in Glaucoma; American Academy of Ophthalmology; March 1980 Vol. 87 Number 3; pgs. 222-228
		Effect of Delta-9-Tetrahydrocannabinol on Intraocular Pressure in Humans; August 1977; Southern Medical Journal Vol., 70 No. 8; pgs. 951-954
		ANTIEMETIC EFFECT OF Delta-9-Tetrahydrocannabinol in patients receiving Cancer Chemotherapy; New England Journal of Medicine; October 16, 1975, Vol. 293 No. 16 pgs. 795-797

		Comparison of Ozone Size Distributions from Pressurized Aerosols Formulations or Suspensions; Pharmaceutical Research Vol. 5 No. 1, 1988, Plenum Publishing Corp. pgs. 36-39
		Changing to CFC-Free Inhalers: The Technical and Clinical challenges; The Pharmaceutical Journal Vol. 259; November 29, 1997; pgs 896-898
		Drug-surfactant-propellant interactions in HFA-formulations; International Journal of Pharmaceutics; 186 (1999) 13-30
		Drug form Selection in Albuterol-containing Metered-Dose Inhaler Formulations and its Impact on Chemical and Physical Stability; Journal of Pharmaceutics Sciences; Vol 86 No. 12, December 1997 pgs. 1352-1357
		The Identification, isolation, and preservation of 9-tetrahydrocannabinol Detp. Of Toxicology, Indiana University Med. Ctr., J. Pharm. 1971, 23, 190-195
		Stability of Tetrahydrocannabinols I J. Pharmaceutics Sciences Vol. 63, No. 10., October 1974; pgs. 1563-1574

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Notice of References Cited				Application No. 09/944221		Applicant(s) JOANNE PEART ET AL.	
				Examiner AARON J. LEWIS		Group Art Unit 3761	
Page 1 of 2							

U.S. PATENT DOCUMENTS						
		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS
	A	4,087,546	5/1978	ARCHER ET AL.	424	283
	B	4,087,547	5/1978	ARCHER ET AL.	424	283
	C	4,464,378	8/1984	HUSSAIN	424	260
	D	4,476,140	10/1984	SEARS ET AL.	424	283
	E	4,847,290	7/1989	BURSTEIN	514	454
	F	4,635,651	1/1987	JACOBS	131	270
	G	5,502,076	3/1996	DIXIT ET AL.	514	510
	H	5,538,993	7/1996	MECHOULAM ET AL.	514	454
	I	7 4,653,961	8/1997	MCNALLY ET AL.	424	45
	J	5,683,676	11/1997	AKEHURST ET AL.	424	45
	K	5,776,433	7/1998	TZOU ET AL.	424	45
	L	5,804,592	9/1998	VOLICER	514	454
	M	5,976,574	11/1999	GORDON	424	489

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS
	N						
	O						
	P						
	Q						
	R						
	S						
	T						

NON-PATENT DOCUMENTS	
	DOCUMENT (Including Author, Title, Source, and Pertinent Pages)
U	
V	
W	
X	

Notice of References Cited				Application No. 09/944221		Applicant(s) JOANNE PEART ET AL.	
				Examiner AARON J. LEWIS		Group Art Unit 3761	

U.S. PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	
A	5,980,867	11/1999	TZOU ET AL.	424	45	
B	5,981,572	11/1999	ELLIS ET AL.	514	456	
C	5,985,248	11/1999	GORDON ET AL.	424	46	
D	6,001,336	12/1999	GORDON	424	46	
E	6,017,963	1/2000	ALFONSO ET AL.	514	646	
F	6,039,932	3/2000	GOVIND ET AL.	424	45	
G						
H						
I						
J						
K						
L						
M						

FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS
N						
O						
P						
Q						
R						
S						
T						

NON-PATENT DOCUMENTS		
	DOCUMENT (Including Author, Title, Source, and Pertinent Pages).	DATE
U		
V		
W		
X		

-FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 98-70	SERIAL NO. 09844221
	APPLICANT: J. Peart, et al.	
	FILING DATE: 9-4-01	GROUP:

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPRO.)

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

	Asgharian, B., Wood, r. & Schlesinger, R.B. (1995). Empirical modeling of particle deposition in the alveolar region of the lungs: A basis for interspecies extrapolation. Fund Appl toxicol, 27, 232-238.
	Barnett, C., Chiang, C., Perez-Reyes, M. & Owens, S. (1982). Kinetic study of smoking marijuana. J. Pharmacokin Biopharm, 10, 495-506
	Byron, P.R. (1994) Dosing reproducibility from experimental albuterol suspension metered-dose inhalers. Pharm Res, 11, 580-4.
	Chiang, C.W. & Barnett, G. (1984). Marijuana effect and delta-9tetrahydrocannabinol plasma level. Clin Pharmacol Ther, 36-234-238.
	Christensen, H.d., Freudenthal, R.I., Gidley, J.T., Rosenfeld, R., Boegli, G., Testino, L., Brine, D.R., Pitt, C.G., & Wall, M.E., (1971) Activity of Delta8-and Delta-9-tetrahydrocannabinol and related compounds in the mouse. Science, 172, 165-167
	Compton, D., Aceto, M., Lowe, J. & Martin, B. (1996) In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J. Pharmacol Exp. Ther, 277,586-594.
	Compton, D.R., Rice, K.C., De Costa, B.R., Razdan, R.K., Melvin, L.S., Johnson, M.R. & Marin, B.R. (1993). Cannabinoid structure-activity relationships: Correlation of receptor binding and in vivo activities. J. Pharmacol Exp Ther, 265, 218-226.
	Cone, E. & Huestis, M., (1993). Relating blood concentrations of tetrahydrocannabinol and metabolites to pharmacologic effects and time of marihuana usage. Ther Drug Mon, 15, 527-532.
	D'Amour, F.E. & Smith, D.L. (1941) A method for determining loss of pain sensation. J. Pharm Exp Ther, 72, 74-79
	Ford, R.D., Balster, R.L., Dewey, W.L., & Beckner, J.S., (1977). Delta 9-THC and 11-OH-delta 9-THC: Behavioral effects and relationship to plasma and brain levels. Life Sci., 20, 1993-20004.
	Gill, E. W. & Jones, J. (1972) Brain levels of delta 1-tetrahydrocannabinol and its metabolites in mice-correlation with behavior, and the effect of the metabolic inhibitors SKF 525A and piperonyl butoxide. Biochem. Pharmacol., 21, 2237-2248.
	Gupta, P.K. & Hickey, A. J. (1991). Contemporay approaches in aerosolized drug delivery to the lungs. J. Controlled release, 17, 129-148.
	Henderson, R., Tennant, F., & Guernsey, R. (1972) Respirory manifestations of hashish smoking. Arch Otol, 95, 248-251.
	Hiller, F.C., Wison, F.J.J., Mazumder, M.K., Wison, J.D. & Bone, R.C., (1984) Concentration and particle size distribution in smoke from marijuana cigarettes with different delta 9-tetrahydrocannabinol content. Fundam Appl Toxicol, 4,451-454.
	House-of-Lords-Select-Committee-on-Science-and-Technology (1998). Ninth Report. Cnnabis: The Scientific and Medical Evidence.
	Huber, G.L., Simmons, G.A., McCarthy, C.R., Cutting, MB., Laguarda, R. & Pereira, W. (1975) Depressant effect of marijuana smoke on antibactercidal activity of pulmonary alveolar macrophages. Chest, 68, 769-73.
	Huestis, M.A., Sampson, A.H., Holicky, B.J., Henningfield, J.E. & Cone, E.J. (1992) Characterization of the absorption phase of marijuana smoking. Clin Pharmacol Ther, 52, 31-41.
	Johansson, E., Ohlsson, A., Lindgren, J.E., Agurell, S., Gillespies, H. & Hollister, L.E. (1987) Single-dose kinetics of deuterium-labelled cannabiniol in man after intravenous adminisitation and smoking. Biomed Envirom Mass Spectrum, 14, 495-499

		Lichtman, A.H., Peart, s, J.L., Bridgen, D.T., Razdan, R.K., Wilsen, D.M., Poklis, leng, Y., Byron, P.R. & Martin, B.R. (2000) Pharmacological evaluation of aerosolized cannabinoids in mice. Eur J. Pharmacol, 399, 11-149.
		Lichtman, A.H., Poklis, J.L., Poklis, A., Wilson, D.M. & Martin, B.R. (2001) The pharmacological activity of inhalation exposure to marijuana smoke in mice. Drug Alc Depend 63, 107-116.
		Little, P.J., Compton, D.r., Johnson. MR., Melvin, L.S. & Martin, B.R. (1988) Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J. Pharmacol Exp Ther, 247, 745-747.
		Mattes, R.D., Shaw, L.M., Edling-Owens, J., Engleman, K. & Elsohly, M.A. (1993) Bypassing the first-pass effect for the therapeutic use of cannabinoids. Pharmacol Biochem Behav, 44, 745-747
		Matthias, P., Tashkin, DP., Marques-Magallanes, J.A., Wilkins, J.N. & Simmons, M.S. (1997) Effects of Varying Marijuana Potency on Deposition of Tar and Delta 9-THC in the Lung During Smoking. Pharmacol Biochem Behav. 58, 1145-1150.
		Ohlsson, A., Lindgren, J.E., Wahlem, A., Agurell, S., Hollister, L. E. & Gillespie, H.K. (1980) Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther, 28, 409-16.
		Ohlsson, A., M. Widman, M., Carlsson, S., Ryman, t., & Strid, C. (1980) Plasma and brain levels of delta 6-THC and seven monooxygenated metabolites correlated to the cataleptic effect in the mouse. Acta Pharmacol. Et Toxicol., 47, 308-317
		Perlin, E., Smith, C.G., Nichols, A.I., Almiraz, r., Flora, K.P., Craddock, J.C. & Peck, C.C. (1985) Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey. J. Pharm Sci, 74, 171-174.
		Prinaldi-Carmona, M., Barth, F., Heaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Neliat, G., Caput, D., Ferrara, P., Soubrie, P., Breliere, J.C., & Lefur, G. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. GEBS Lett, 350, 240-244
		Schlesinger, R.B. (1985) Comparative deposition of inhaled aerosols in experimental animals and humans a review. J. Toxicol Environ Health, 15, 197-214
		USP (2000) Physical Tests and Determinations. <601> Aerosols, metered-dose inhalers, and dry powder inhalers. In United States Pharmacopeia (USP 24) PP. 1895-1912. Philadelphia, PA: National Publishing
		Vachon, L., Robins, A. & Gaensler, E.A. (1976) Airways response to aerosolized delta 9-tetrahydrocannabinol: preliminary report. In The Therapeutic potential of marijuana. Ed. Cohem, S. & Stillman, R.C. pp 111-121. New York: Plenum Medical Book Company
		Vaswani, S.K. & Criticos, P.S. (1998) Metered dose inhaler: past, present, and future. Ann Allergy Asthma Immunol, 80, 11-9; quiz 19-20

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.
02940086PASERIAL NO.
09/944,221APPLICANT:
J. Peart, et al.FILING DATE:
September 4, 2001GROUP:
1617

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPRO.)
	5,492,688	02/20/96	P. Byron, et al.			3/23/94
	5,736,124	4/7/98	R. Akehurst, et al.			05/30/95
	5,916,540	6/29/99	R. Akehurst, et al.			4/6/98
	5,922,306	7/13/99	R. Akehurst, et al.			4/15/98

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

		T. Tzou. DENSITY, EXCESS MOLAR VOLUME, AND VAPOR PRESSURE OF PROPELLANT MIXTURES IN METERED-DOSE INHALERS: DEVIATION FROM IDEAL MIXTURES; T. Tzou; Respiratory Drug Delivery. VI, 1998 439-443
		J. H. Bell, et al.; Variation in delivery of isoprenaline from variuos pressurized inhalers. J. Pharm Pharmac, 1973, Suppl. 32P-36P
		F. Moren; Drug Deposition of pressurized inhalation aerosols Influence of vapour pressure and metered volume; Int'l Journal of Pharmaceuticals. 1 (1978) 213-218

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant